Prevalence and Perception of Complementary and Alternative Medicine Use Among Childhood Cancer Patients: A Mixed‐Methods Study
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31975 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Shuvadeep Ganguly und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India. Hauptthemen laut MEDLINE: Complementary Therapies, Neoplasms, Caregivers, Health Knowledge, Attitudes, Practice. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Complementary and alternative medicine (CAM) usage among childhood cancer patients remains understudied. Factors associated with CAM use and motivations of caregivers for using CAM remain poorly understood.
Methods
This cross‐sectional mixed‐methods study was conducted among caregivers of patients aged ≤18 years with confirmed cancer diagnoses. Caregivers were interviewed regarding CAM use, reasons for using/non‐using CAM, and views on CAM. Logistic regression identified factors associated with CAM use, whereas qualitative interviews explored motivations and barriers. The impact of CAM usage on 2‐year overall survival was explored.
Results
Out of 450 respondents, CAM usage was reported by 35.78% ( n = 161), with home remedies (28.44%, n = 128) and AYUSH (Ayurveda, Unani, Siddha, Yoga, Homeopathy) therapies (13.56%, n = 61) being most common. CAM use was associated with symptom duration ≥30 days (adjusted odds ratio [aOR]: 1.71; 95% CI: 1.09–2.67; p = 0·019) and hematological malignancies (aOR: 2.05; 95% CI: 1.33–3.17; p = 0·001). Major motivations for CAM use included belief in effectiveness (44.72%, n = 72) and family recommendations (34.16%, n = 55). Qualitative interviews highlighted cost, accessibility issues, and diagnostic delays as key drivers of CAM adoption. The 2‐year survival probabilities of CAM users and nonusers were comparable (0.88 [95% CI: 0.83–0.94] vs. 0.87 [95% CI: 0.83–0.92], log‐rank p = 0.75).
Conclusion
CAM is frequently used by pediatric cancer patients, driven by caregiver beliefs, family influence, and access barriers. Addressing caregiver practices and integrating CAM discussions into care may enhance supportive strategies without impacting survival outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India.
- Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Leukemia, Dana Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
- Division of Public Health, Kalyan Singh Super Specialty Cancer Institute, Lucknow, India.
ORCID-Profile: Shuvadeep Ganguly, Manraj Singh Sra, Deepam Pushpam, Sameer Bakhshi
Zitieren
APA
Ganguly, S., Singh Sra, M., Sasi, A., Singh, R., Verma, V., Sharma, S., Lohiya, A., Das, A., Pushpam, D., & Bakhshi, S. (2025). Prevalence and Perception of Complementary and Alternative Medicine Use Among Childhood Cancer Patients: A Mixed‐Methods Study. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31975
Vancouver
Ganguly S, Singh Sra M, Sasi A, Singh R, Verma V, Sharma S, et al. Prevalence and Perception of Complementary and Alternative Medicine Use Among Childhood Cancer Patients: A Mixed‐Methods Study. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31975
BibTeX
@article{Ganguly2025,
author = {Ganguly, Shuvadeep and Singh Sra, Manraj and Sasi, Archana and Singh, Ritika and Verma, Vasudha and Sharma, Shubhangi and Lohiya, Ayush and Das, Anubhav and Pushpam, Deepam and Bakhshi, Sameer},
title = {Prevalence and Perception of Complementary and Alternative Medicine Use Among Childhood Cancer Patients: A Mixed‐Methods Study},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31975}
}
EUVIMED